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Abstract
The trafficking protein particle complex 4 (TRAPPC4) is implicated in vesicle-mediated transport, but its association with
disease has rarely been reported. We explored its potential interaction with ERK2, part of the ERK1/2 complex in the
Extracellular Signal-regulated Kinase/ Mitogen-activated Protein Kinase (ERK-MAPK) pathway, by a yeast two-hybrid screen
and confirmed by co-immunoprecipitation (Co-IP) and glutathione S-transferase (GST) pull-down. Further investigation
found that when TRAPPC4 was depleted, activated ERK1/2 specifically decreased in the nucleus, which was accompanied
with cell growth suppression and apoptosis in colorectal cancer (CRC) cells. Overexpression of TRAPPC4 promoted cell
viability and caused activated ERK1/2 to increase overall, but especially in the nucleus. TRAPPC4 was expressed more highly
in the nucleus of CRC cells than in normal colonic epithelium or adenoma which corresponded with nuclear staining of
pERK1/2. We demonstrate here that TRAPPC4 may regulate cell proliferation and apoptosis in CRC by interaction with ERK2
and subsequently phosphorylating ERK1/2 as well as modulating the subcellular location of pERK1/2 to activate the relevant
signaling pathway.
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Introduction
TRAPPC4, the human ortholog of yeast Trs23p, also known as
synbindin, is generally known as a neuronal cytoplasmic protein
originally identified by yeast two-hybrid screening using the
syndecan-2 (belonging to a family of cell-surface heparan sulfate
proteoglycans that regulates cell behavior through signal trans-
duction pathways [1,2,3]) cytoplasmic domain as bait [4]. It is
considered a physiological ligand of syndecan-2 on dendritic spines
that is involved in syndecan-2 induced spine formation by
recruiting intracellular vesicles toward post-synaptic sites in rat
hippocampal neurons. TRAPPC4 has been detected in CD34+
hematopoietic stem/progenitor cells (HSPCs) and thus is also
known as HSPC172.
TRAPPC4 as a member of the trafficking protein particle
(TRAPP) family of proteins is implicated in vesicle-mediated
transport, a process carried out by virtually every cell and is
required for the proper targeting and secretion of proteins. At
present, there are 10 known yeast TRAPP subunits (Bet5p, 3p,
Trs20p, 23p, 31p, 33p, 65p, 85p, 120p, 130p), and higher
eukaryotes have orthologs for eight of these (TRAPP-
C1,5,6a,6b,8,9) [5]. Together, they form two types of mutisubu-
nit complexes: TRAPP I and TRAPP II. In yeast, these complexes
function in a number of processes, including endoplasmic
reticulum-to-Golgi transport (TRAPP I) and an ill-defined step
at the trans Golgi network (TRAPP II) [6,7,8]. Studies in normal
rat kidney (NRK) cells and HeLa cells also showed that the
TRAPP complex plays a role during ER-Golgi transport [9,10].
The PDZL domain in TRAPPC4 is one of the most unique
features of the vertebrate complex when compared with yeast
TRAPP I. Dysfunction of TRAPP subunits have been implicated
in human diseases. Mutations in TRAPPC1 (MUM-2) were
reported to result in expression of antigenic peptides in melanoma
[11], and mutations in TRAPPC2 (sedlin) have been linked to
Spondyloepiphyseal dysplasia tarda (SEDT) [12]. However, the
role of TRAPPC4 in disease has rarely been studied.
Colorectal cancer (CRC) is a significant cause of morbidity and
mortality throughout the world [13]. Colorectal carcinogenesis is a
complex multi-step process involving progressive disruption of
intestinal epithelial-cell proliferation, apoptosis, differentiation
and survival mechanisms [14]. The Extracellular Signal-
regulated Kinase/ Mitogen-activated Protein Kinase (ERK-
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pathways for cellular physiology, and several key growth factors
and proto-oncogenes promote growth and differentiation through
this cascade [15]. Upon activation, the ERK1/2 complex migrates
to the nucleus where it phosphorylates various transcription factors
that regulate genes to increase cell proliferation and modulate cell
apoptosis [16]. However, the detailed mechanisms of activation
and nuclear translocation of ERK1/2 have not been fully clarified.
In the current study, a yeast two-hybrid screen was performed
to identify ERK1 and ERK2 binding proteins. TRAPPC4 was
found to bind with ERK2. We confirmed the interaction and
further investigated the role of the TRAPPC4-ERK2 interaction
in CRC.
Results
TRAPPC4 was identified as an ERK2-interacting factor by
two-hybrid screening
Phosphorylation and nuclear entry of ERK1/2 is critical for
activation of the ERK-MAPK pathway. To identify factors related
to the process, a yeast two-hybrid screen was performed with
ERK1 and ERK2 as baits (full-length) in conjunction with a
human HeLa MATCHMAKER cDNA library. Of the colonies
growing on Leu-Trp-His plates that were screened, 57/61 were
positive for ERK2 and 12/32 for ERK1 in a ß-galactosidase assay.
Plasmids from these positive colonies were extracted, amplified in
bacteria and co-transformed back into yeast along with the bait
plasmids for further testing by ß-galactosidase assay. Eleven clones
were confirmed to have a positive interaction with ERK2 and
twelve with ERK1. Among these plasmids that were positive hits
for ERK2 and ERK1, TRAPPC4 was identified in five and six of
the sequences, respectively, after sequencing. This was the first
time that TRAPPC4 was identified as a potential interacting
protein of ERK2.
Validation of the TRAPPC4-ERK2 interaction
To further confirm the interaction between TRAPPC4 and
ERK2, co-immunoprecipitation and GST pull-down experiments
were conducted. For co-immunoprecipitation, full-length TRA
PPC4 cDNA was obtained and cloned into pCDEF-Myc, while
the ERK2 sequence was cloned into pCDEF-Flag. The resulting
pCDEF-Myc-TRAPPC4 and pCDEF-Flag-ERK2 vectors were
validated by sequencing and co-transfected into the 293T cell line.
Western blot analysis (Fig. 1A) showed that the plasmids could
express significant levels of the proteins. After using an anti-Myc
antibody for co-immunoprecipitation, both the TRAPPC4-myc
band and ERK2-flag band were detected from the pCDEF-Myc-
TRAPPC4 and pCDEF-Flag-ERK2 co-transfected cells, indicat-
ing there is an interaction between TRAPPC4 and ERK2. In the
positive control sample with co-transfected pCDEF-Myc-p16 and
pCDEF-Flag-TSSK1 vectors, both the p16-Myc band and TSSK-
flag band were detected, indicating that the proteins could be co-
immunoprecipitated by our protocol based on the known
interaction between p16 and TSSK1. Only the TRAPPC4-myc
band was detected when pCDEF-Myc-TRAPPC4 was co-
transfected with an empty flag vector, while no band was detected
when pCDEF-Flag-ERK2 was co-transfected with empty Myc
vector, suggesting that the interactions observed above are specific
and not mediated by the protein tags.
As it is possible that the TRAPPC4 and ERK2 interaction may
be indirect because other protein factors in the whole cell extract
may be involved in mediating the interaction, e.g. acting as
‘bridging’ factors, we next examined a possible direct interaction
between the two proteins using GST pull-down assays. TRAPPC4
was pulled down with GST-ERK2 fusion proteins (Fig. 1B, lane c),
but not with GST alone (Fig. 1B, lane b), indicating that
TRAPPC4 and ERK2 specifically and directly interacted in vitro.
TRAPPC4 regulates ERK1/2 phosphorylation in the
SW1116 cell line
Phosphorylation of ERK1/2 is a critical step in the ERK
signaling pathway. Now that we had shown that TRAPPC4
interacted with ERK2, we next examined the relative contribution
of TRAPPC4 in ERK1/2 phosphorylation. After reducing the
expression level of TRAPPC4 in SW1116 cells by RNAi or
overexpressing it by transfection of a plasmid encoding the full-
length gene, we determined the change in pERK levels by
Western blotting. Detection of GAPDH was used as a loading
control. While there were no observed differences in the protein
levels of total ERK1/2 in all the groups (Fig. 2), the
phosphorylation level of ERK1/2 was down-regulated after
siRNA -mediated depletion of TRAPPC4 (Fig. 2A) and up-
regulated after its overexpression (Fig. 2B). Furthermore, we
treated both groups of cells with platelet-derived growth factor
(PDGF), one of the activators of the ERK-MAPK pathway, and
found that the level of ERK1/2 phosphorylation after the
treatment was not significantly different between the groups,
despite their differences in TRAPPC4 levels (Fig. 2).
TRAPPC4 regulates the spatial distribution of
phosphorylated ERK1/2
Since we had shown that TRAPPC4 could influence the
activation status of ERK1/2, we wanted to determine its effect on
the subcellular localization of pERK1/2. Next, we compared
pERK1/2 and ERK1/2 expression in the separated cytoplasmic
and nuclear fractions when TRAPPC4 was depleted or overex-
pressed as described above. Again, GAPDH was used as a loading
control for cytoplasmic protein input, and TBP was used as a
control for nuclear protein input.
By Western blotting, we found that after TRAPPC4 siRNA
treatment, the level of pERK1/2 significantly decreased in the
nucleus (Fig. 3A). Meanwhile, no significant difference in pERK1/
2 was found in the cytoplasm when quantified, even though a
slight increase was suggested visually (Fig. 3B). On the other hand,
when TRAPPC4 was overexpressed, pERK1/2 expression was
upregulated significantly in the nucleus (Fig. 4A). While in the
cytoplasm, our results showed a slight visual increase without
significant differences when quantified (Fig. 4B).
PDGF can activate the ERK-MAPK pathway through receptor
tyrosine kinases [17]. When the SW1116 cell line was stimulated
with PDGF, a slight decrease of pERK1/2 was visually observed
in the nuclear fraction after TRAPPC4 knock-down, but it was not
significant upon quantification. Meanwhile, no significant alter-
ation in pERK1/2 was quantified in the cytoplasmic fraction, even
though a slight increase was suggested visually (Fig. 3). However,
PDGF stimulation of cells overexpressing TRAPPC4 resulted in
significant pERK1/2 upregulation in the nucleus, but not in the
cytoplasm (Fig. 4).
TRAPPC4 modulates proliferation and depletion of
TRAPPC4 induces apoptosis in the SW1116 cell line
The activation of ERK-MAP kinases has been linked to cell
proliferation [16]. To further study the function of TRAPPC4 in
CRC cells, we compared cell proliferation of SW1116 cells when
TRAPPC4 expression was decreased by siRNA or over-expressed
with full-length TRAPPC4 gene transfection with that of mock
control. Results of the Cell Counting Kit (CCK)-8 assay revealed a
TRAPPC4-ERK2 Interaction Plays a Role in CRC
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increase of cell viability when TRAPPC4 was overexpressed both
starting from 24 h post-transfection (Fig. 5A).
TRAPPC4 accumulation in the nucleus is associated with
pERK1/2 staining in human colorectal cancers
As little was known about the expression and localization of
TRAPPC4 in colorectal cancer in vivo, we then compared its
expression in normal colonic epithelium, adenoma and adenocar-
cinoma tissues by immunohistochemistry as described in Materials
and methods. In normal colonic epithelium, TRAPPC4 staining
was restricted to the cytoplasm (Fig. 6A). 4.55% of the cells in the
adenoma samples showed nuclear staining, while it was 55.89% in
the adencarcinoma samples (p,0.01). No significant differences
were shown in total TRAPPC4 expression between the three
groups (normal colonic epithelium group=85.7%; adenoma
group=72.7%; adenocarcinoma group=79.4%; p.0.05).(Tab. 1)
Moreover, we analyzed the association between TRAPPC4 and
pERK1/2 or ERK1/2 staining in normal colonic epithelium,
adenoma and adenocarcinoma. While ERK1/2 staining was detected
both in the cytoplasm and nucleus (Fig. 6C), its staining in the nucleus
increased significantly in the adenocarcinoma group compared to the
other two groups. Furthermore, the pERK1/2 activated proteins were
all located in the nucleus, and there were significant differences among
the three groups (Fig. 6B). Thus, our results demonstrate a significant
correlation between nuclear TRAPPC4 expression and pERK1/2
levels (r=0.996), and also between nuclear TRAPPC4 expression and
ERK1/2 levels (r=0.994).
Discussion
The two components of the ERK1/2 complex are always found
to be co-localized in colorectal carcinomas [17,18,19,20], and the
ERK1 and ERK2 MAPKs have attracted intense research interest
because of their critical involvement in the regulation of cell
proliferation and surviva [17]. Activated ERKs phosphorylate and
regulate the activities of an ever growing roster of substrates that
are estimated to comprise over 160 proteins [21]. Therefore,
ERK1 and ERK2 were used as bait for two-hybrid-yeast screening
in a human Hela cDNA library in the first step of this study. As a
result, among the 23 binding proteins (11 with ERK2 and 12 with
ERK1), the possible interaction of TRAPPC4 and ERK2 but not
with ERK1 was revealed for the first time. Our co-immunopre-
cipitation and GST-pulldown experiments further confirmed
TRAPPC4 as an ERK2 interaction partner.
Since little evidence of TRAPP proteins in CRC has been
reported, and the role of the TRAPPC4-ERK2 interaction is still
unknown, we first analyzed the effect of TRAPPC4 on
phosphorylated ERK1/2, the activated form of ERK1/2. We
found that, as a whole, overexpression of TRAPPC4 activated
ERK1/2, while its depletion decreased pERK1/2 levels in the
colon cancer-derived cell line SW1116. Thus, TRAPPC4 acts as a
positive regulator for pERK1/2.
Although some are found in the cytoplasm, the majority of ERK
substrates are nuclear proteins [22]. Activated ERKs can
translocate to the nucleus where they phosphorylate and regulate
various transcription factors, such as Ets family transcription
Figure 1. Identification of the protein-protein interaction between TRAPPC4 and ERK2 by co-immunoprecipitation and pull-down
assay. A: Co-immunoprecipitation of TRAPPC4 and ERK2. 293T cells were transfected with empty pcDNA vector or pcDNA vector to express Flag
tagged ERK2 (42 kD), or Myc tagged TRAPPC4 (26 kD). Cell lysates were subjected to immunoprecipitation with anti-Flag-HRP antibody or anti-Myc-
HRP antibody. The presence of ERK2-Flag and TRAPPC4-Myc in cell extracts prior to immunoprecipitation was controlled using anti-Flag and anti-Myc
antibodies (Input). Co-transfection of expression vectors for p16-Myc and TSSK1-Flag was used for the positive control (lane 1). B: Representative
results of GST pulldown validation experiments. (a) Immunoblot analysis of GST, and GST-ERK2 proteins used as negative control (lane 2) and bait
(lane3) for the pulldown assay. Proteins were detected using anti-66HIS antibody following SDS-PAGE and membrane transfer. Lane 1 showed the
blank control without GST or GST-ERK2. (b) ERK2 expressed as a GST fusion protein from bacteria was bound to beads and incubated with TRAPPC4
expressed as 66His-TRAPPC4 fusion protein for a pulldown experiment. GST-ERK2 protein(lane1), GST protein(lane2) and TRAPPC4 protein(lane4)
were detected by Coomassie staining. Lane3 showed the marker.
doi:10.1371/journal.pone.0023262.g001
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Further assessment of cytoplasmic and nuclear fractions showed
that the location of pERK1/2 also altered along with TRAPPC4
expression levels. When TRAPPC4 was knocked down, the
nuclear pERK1/2 level was notably down-regulated, but no
significant difference was shown in the cytoplasm. When
overexpressed, pERK1/2 expression increased both in the nucleus
and cytoplasm, but more remarkably in the nucleus. Thus,
TRAPPC4 is involved in not only the phosphorylation of ERK1/2
but also its spatial distribution in colorectal epithelial cells. TRAPP
proteins are known to be part of a large multi-protein complex
involved in ER-to-Golgi and intra-Golgi trafficking [5,7,8]. They
present as several isoforms which differ in subunits, function, and
location. For example, TRAPPCI is involved in the recruitment of
ER-derived vesicles to the cis-Golgi [8], and TRAPPCII [7] is
required for retrograde transport from the endosomes. Eva Loh
et al. revealed that Bet3, the most conserved component of the
TRAPP complex, is expressed in eight different mouse tissues,
exists in two distinct pools in the cytosol and functions during ER-
Golgi transport [10]. Therefore, TRAPPC4 may play a role in
Figure 2. Expression of TRAPPC4 influences the activation status of ERK1/2 in CRC cells. Cells were lysed, and equal amounts of protein
were analyzed by Western blot analysis using antibodies against phospho-ERK1/2 (pERK1/2), or ERK1/2, or TRAPPC4. The density of the Western blot
bands were normalized to the amount of GAPDH protein. The data shown are representative of three replicate experiments. *,p,0.05. A. Cells were
transfected with TRAPPC4 siRNA (siTRAPPC4) to knockdown TRAPPC4 expression or with Negtive Control siRNA (siControl) as control; Also cells were
treated with PDGF to activate ERK-MAPK pathway, or with its solvent (PBS+0.1 BSA) as control. B. Cells were transfected with pCDEF-myc-TRAPPC4
vector to overexpress TRAPPC4 protein or with pCDEF-myc vector as control; Also cells were treated with PDGF to activate ERK-MAPK pathway, or
with its solvent (PBS+0.1 BSA) as control.
doi:10.1371/journal.pone.0023262.g002
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mechanism will require additional study.
PDGF can signal through the ERK-MAPK pathway and
activate the ERK cascade through receptor tyrosine kinases. We
found that after treatment with PDGF, the effect of TRAPPC4 on
pERK1/2 was completely or partially obscured. The results gave
us an indication that TRAPPC4 may be involved in certain steps
of PDFG-mediated activation of the ERK1/2 cascade. As for
ERK1/2 phosphorylation, the effect of TRAPPC4 may not be as
potent as that of PDGF. However, the detailed mechanism
remains to be thoroughly investigated.
Moreover, we found that TRAPPC4 affected cell prolifera-
tion as well as cell death. Depletion of TRAPPC4 inhibited cell
growth and induced apoptosis, while its overexpression contrib-
uted to cell growth. It was reported that activated ERK1/2
interacts with some substrates, such as Phosphoprotein enriched
in astrocytes 15 (PEA-15),and Death associated protein kinase
(DAPK), and is sequestered in the cytoplasm [24]. Deletion of
PEA-15 markedly stimulates ERK-dependent proliferation and
gene transcription; while PEA-15 overexpression blocks the
proliferation via its ability to bind and sequester ERK1/2 in the
cytoplasm [25]. DAPK sequesters ERK1/2 in the cytoplasm by
interacting with ERK through a D-domain within its death
domain. and the interaction promotes the proapoptotic function
of DAPK [26]. Therefore, inhibition of ERK1/2 nuclear
localization impairs ERK1/2-mediated survival signals and in
addition augments the proapoptotic signals. In our study, after
knockdown of TRAPPC4, the decrease in activation of ERK1/2
corresponded with less nuclear localization, which may
ultimately lead to growth surpression and apoptosis. Whereas,
more nuclear localization when TRAPPC4 overexpressed may
promote cell growth.
Figure 3. Knockdown of TRAPPC4 decreased actived ERK1/2 level in nucleus on SW1116 cell line. SW1116 cells were transfected with
TRAPPC4 siRNA (siTRAPPC4) to knockdown TRAPPC4 expression or with Negtive Control siRNA (siControl) as control; Also cells were treated with
PDGF to activate ERK-MAPK pathway, or with its solvent (PBS+0.1% BSA) as control. Cytoplasm and nuclear extracts were prepared as described in
experimental procedures, and equal amounts of protein were analyzed by Western blot analysis using antibodies against phospho-ERK1/2 (pERK1/2),
or ERK1/2, or TRAPPC4. The density of the Western blot bands were normalized to the amount of GAPDH protein for cytoplasma protein or TBP for
nuclear protein. The data shown are representative of three replicate experiments. *,p,0.05.
doi:10.1371/journal.pone.0023262.g003
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focused on yeast and normal mammalian cells or tissues [4,5,8,10].
To our knowledge, only expression of TRAPPC2 has been
investigated in the disease of SEDL [27]. To date, the location of
TRAPP subunits has mainly been reported in the cytoplasm of
mammaliancells[9,10].TRAPPC4 wasreportedlylocatedinspines
of cultured hippocampal neurons [4], but little information on its
role in disease has been obtained. Here, we analyzed TRAPPC4
expression in human normal colonic epithelium, adenoma, and
adenocarcinoma tissues by immunohistochemistry. The results
revealed that nuclear TRAPPC4 appears after normal epithelium
tissue progresses to adenoma and adenocarcinoma. Thus, the
alteration in localization of TRAPPC4 may be related to colorectal
carcinogenesis. The question remains whether it may result from
anygene mutationsorstructuralmodificationsarising inTRAPPC4
during colorectal carcinogenesis.Meanwhile, pERK1/2, which was
localized in the nucleus in our study, increased in adenocarcinoma
compared to adenoma tissues and normal epithelial tissues. As
mentioned above, the main function of the TRAPP family is in
regulation of vesicular transport, and TRAPPC4 is involved in
membrane trafficking in post-synaptic sites in neurons. One could
askifthemechanismofnuclearlocalizationofTRAPPC4inCRCis
relevant to the transport of pERK1/2 from the cytoplasm to the
nucleus. In fact, the TRAPP complex was shown to act as the
guanine nucleotide exchange factor (GEF) for Ypt1 and Ypt31/32
GTPases both in vitro and in vivo [28,29]. While Ypt1 GTPase is
required at the cis-Golgi for the targeting and fusion of ER-derived
vesicles [30,31], the functions of the Ypt31/32 GTPases are also
Figure 4. Overexpression of TRAPPC4 increased actived ERK1/2 level in nucleus on SW1116 cell line. SW1116 cells were transfected
with pCDEF-myc-TRAPPC4 vector to overexpress TRAPPC4 protein or with pCDEF-myc vector as control; Also cells were treated with PDGF to activate
ERK-MAPK pathway, or with its solvent (PBS+0.1% BSA) as control. Nuclear (A) and cytoplasm (B) extracts were prepared as described in experimental
procedures, and equal amounts of protein were analyzed by Western blot analysis using antibodies against phospho-ERK1/2 (pERK1/2), or ERK1/2, or
TRAPPC4. The density of the Western blot bands were normalized to the amount of TBP for nuclear protein or GAPDH protein for cytoplasma protein.
The data shown are representative of three replicate experiments. *,p,0.05.
doi:10.1371/journal.pone.0023262.g004
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be seen whether a similar molecular mechanism exists for
TRAPPC4 in CRC in yet further studies.
In conclusion, our study demonstrated the interaction of
TRAPPC4 with ERK2. In colorectal cancer, it not only regulates
the activation of ERK1/2 but also affects the distribution of
activated ERK1/2. It modulates cell proliferation and apoptosis in
CRC cells. In consideration with previous studies, we speculate
that, in CRC, TRAPPC4 binds and activates ERK1/2 as well as
participates in the nuclear transport of pERK1/2. When
TRAPPC4 is depleted, less ERK1/2 is phosphorylated, and
relatively more pERK1/2 remains in the cytoplasm, which leads
to suppression of cell proliferation and apoptosis. When
TRAPPC4 is overexpressed, more ERK1/2 is activated, and
even more is transported into the nucleus, finally leading to
increased cell growth (Fig. 7). Future studies will be required to
clarify this proposed molecular mechanism.
Materials and Methods
Plasmids and transfections
The full-length ERK1, ERK2, and TRAPPC4 cDNA were
obtained by PCR from a human cDNA library. For yeast two-
hybrid assays, full-length fragments of ERK1 and ERK2 cDNAs
were cloned both in frame with the SfiI site in the pGB plasmid.
For binding assays, the full-length TRAPPC4 cDNA was cloned in
pCDEF-Myc, and full-length ERK2 cDNA was cloned in
pCDEF-Flag. ERK2 was subcloned in pGEX-5x to produce
Figure 5. Expression of TRAPPC4 inflenced cell growth and its depletion induced apoptosis on SW1116. A: CCK-8 assay. SW1116 cells
were seeded in a 96-well plate until subconfluent. Viable cells were determined by CCK-8 assay. Three independent time were performed in
triplicate. Cells were treated with TRAPPC4 siRNA to knockdown TRAPPC4 expression or with Negtive Control siRNA used as control (a), as well
as tranfered with pCDEF-myc-TRAPPC4 vector to overexpressT R A P P C 4p r o t e i no rw i t hp C D E F - m y cv e c t o ra sc o n t r o l( b ) .* ,p,0.05. B: Apoptosis
analysis. After SW1116 cells were treated with TRAPPC4 siRNA or Negtive Control siRNA used as control for 48 h. Apoptosis was carried out
using the Annexin V assay with Propidium iodide counterstaining allowing quantification by flow cytometry. Three independent time were
performed in triplicate. The data were presented as means 6 standard deviation (SD). There was significant difference between the two groups(
p,0.01).
doi:10.1371/journal.pone.0023262.g005
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was subcloned in pET-28a to produce His fusion proteins.
For the co-immunoprecipitation experiments below, 1.6610
6
cells/well of 6-cm dishes were co-transfected with vectors
pCDEF-Myc-TRAPPC4 and pCDEF-Flag-ERK2 expressing
TRAPPC and ERK2, respectively, using a plasmid: transfection
reagent ratio of 1:4 (4 mg each plasmid). Empty vector controls
were pCDEF-Myc or pCDEF-Flag (both from Shanghai
Genomics).
Yeast two-hybrid assays
Yeast two-hybrid screening was performed to identify ERK1
and ERK2 interacting proteins by using the Clontech Match-
maker Two-Hybrid System (Cat. #K1612-1) according to the
manufacturer’s instructions. Bait plasmids PGB-ERK1-G and
PGB-ERK2-G were transformed into the yeast strain Y190.
Toxicity effects and self-activation tests were performed using a b-
galactosidase assay. Yeast transformed with bait plasmids were
cultured and screened with the human HeLa Matchmaker cDNA
library (Clontech, CAT#HL4048AH) and then grown on Leu-
Trp-His plates for selection and validation using the ß-galactosi-
dase assay. Plasmids from positive colonies were extracted,
amplified in bacteria and co-transformed back into yeast along
with the bait plasmids for further testing in ß-galactosidase assays.
Plasmids of positive hits were sequenced and analyzed.
Co-immunoprecipitation (co-IP) and GST-pulldown
analysis
Co-immunoprecipitation was performed as described previously
[33]. Both the input and IP samples were analyzed by Western
blot using various antibodies at the following dilutions: Flag
Antibody (1:1000), Myc Antibody (1:1000) Flag-HRP Antibody
(1:4000), Myc-HRP Antibody (1:2000) (all from Shanghai
Genomics, Shanghai, China), and goat anti-mouse IgG-HRP
Antibody (1:5000) (Santa Cruz Biotechnology, Santa Cruz,
U.S.A.). Co-transfection of expression vectors for p16 and TSSK1
(Shanghai Genomics, Shanghai, China) was used for the positive
control co-immunoprecipitation.
GST protein and GST-ERK2 fusion proteins were expressed
and purified according to manufacturer’s instructions (GE
Figure 6. Representative immunohistochemical examination of TRAPPC4. (A), pERK1/2 (B) and ERK1/2 (C) in normal colonic epithelium (a),
adenoma (b), and adenocarcinoma (c). Polygrams(d)show expression of the proteins in cytoplasm (pink), nucleus (yellow), and total (blue).
A: Expression of TRAPPC4 has no significant difference in the three groups totally, but increases in nucleus from a to c. B: pERK1/2 mainly located in
nucleus, and its level increases significantly from a to c. C: Expression of ERK1/2 has no significant difference in the three groups totally, but increases
in nucleus from a to c. Original magnification 6200.
doi:10.1371/journal.pone.0023262.g006
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the GST or GST fusion proteins were mixed with 40 ml of a
50% suspension of glutathione-Sepharose 4B beads for 2 h in
binding buffer [25 mM HEPES-NaOH (pH 7.5), 12.5 mM
MgCl2 10% Glycerol, 5 mM DTT, 0.1% NP-40, 150 mM
KCl and 20 mM ZnCl2]. Then 1–5 mg of 66His-TRAPPC4
fusion proteins was added followed by incubation for another
2 h. The pellets were washed extensively, and were identified by
western blotting with 66His Antibody (1:1000) (Abcam, Cam-
bridge, U.K.).
Figure 7. The speculated role of TRAPPC4-ERK2 interaction in CRC. Extracellular signals, such as PDGF, activate ERK cascades(RAS/RAF/MER/
ERK) through receptor tyrosine kinases (RTKs) and utimately regulate cell proliferation and apoptosis. TRAPPC4 binds and activates ERK1/2 as well as
participates in the nuclear transport of pERK1/2. When TRAPPC4 is depleted, less ERK1/2 is phosphorylated, and relatively more pERK1/2 remains in
the cytoplasm, which leads to suppression of cell proliferation and apoptosis. When TRAPPC4 is overexpressed, more ERK1/2 is activated, and even
more is transported into the nucleus, finally leading to increased cell growth.
doi:10.1371/journal.pone.0023262.g007
Table 1. Frequency of Expression of TRAPPC4, pERK1/2 and ERK1/2.
Normal epithelium(%) Adenoma(%) Adenocarcinoma(%)
TRAPPC4
Nucleus* 0 (0.0) 1 (4.5) 19 (55.9)
Cytoplasm* 12 (85.7) 15 (68.2) 11 (32.4)
Total* 12 (85.7) 16 (72.7) 27 (79.4)
pERK1/2
Nucleus 0 (0.0) 1 (4.5) 9 (26.5)
Cytoplasm 0 (0.0) 4 (18.2) 0 (0.0)
Total 0 (0.0) 4 (18.2) 9 (26.5)
ERK1/2
Nucleus 0(0.0) 2(9.1) 16(47.1)
Cytoplasm 13(92.9) 12(54.5) 13(38.2)
Total 13(92.9) 12(54.5) 24(70.6)
Number of samples 14 22 34
*Nucleus, nuclear staining; Cytoplasm, cytoplasmic staining; Total, staining in nucleus or cytoplasm or both.
doi:10.1371/journal.pone.0023262.t001
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The colon cancer-derived cell line SW1116 (purchased from the
Cell Bank of Type Culture Collection of Chinese Academy of
Sciences, Shanghai Institute of Cell Biology, Chinese Academy of
Sciences) was maintained by serial passages in RPMI 1640
containing 10% heat-inactivated fetal calf serum (FCS), 100 units/
ml penicillin and 100 mg/ml streptomycin. Human 293T cells
(purchased from the Cell Bank of Type Culture Collection of
Chinese Academy of Sciences, Shanghai Institute of Cell Biology,
Chinese Academy of Sciences) were maintained in DMEM
supplemented with 10% FCS and antibiotics. Cultures were
incubated at 37uC in standard tissue culture incubators as
previously described (5). A total of 106 cells were plated per
100-mm dish. Platelet-derived growth factor (PDGF) (Sigm-
Aldrich, St. Louis, U.S.A.) was used to sitimulated SW1116 cells
at a final concentration of 10 ng/ml for 15 min.
RNAi and transient transfections
TRAPPC4 expression was inhibited using ON-TARGETplus
SMARTpool siRNA and DharmaFECT transfection reagent
(Thermo Fisher Science, Inc., Rockfrd, USA) according to the
manufacturer’s instructions. Briefly, SW1116 were seeded in 12-
well plates in medium containing 10% serum at a density that
would allow cells to reach 50% confluence on the day of
transfection. The transient transfections were performed using
100 nM of each siRNA duplex. siGLO RISC-Free Control siRNA
was used as a negative control. The selective silencing of
TRAPPC4 was confirmed by Western blot analysis.
Western blot assays
Western blot assays were performed to examine the phosphor-
ylation of ERK1/2 and expressions of total ERK1/2 and
TRAPPC4 proteins. Cytoplasmic and nuclear extracts were
prepared with NE-PERH Nuclear and Cytoplasmic Extraction
Reagents (Thermo Fisher Scientific, Inc., Rockfrd, USA
)according to the manufacturer’s instructions, and whole cell
extracts were prepared by a previously described method [34]
from both siRNA-treated TRAPPC4-plasmid treated and mock-
treated, or transfected and mock-transfected SW1116 cells. After
electrophoresis, 400 mg of proteins were electroeluted at 120 volts
onto a polyvinylidene difluoride membrane (Invitrogen, Califor-
nia, U.S.A.). Primary antibodies raised against phosphorylated
ERK1/2 (Thr202/204) and ERK1/2 were purchased from Cell
Signaling Technology (Danvers, U.S.A.). The anti-TRAPPC4
antibody was purchased from Sigm-Aldrich (St. Louis, U.S.A.),
and the GAPDH (Sigm-Aldrich, St. Louis, U.S.A.) antibody was
used as a control for total and cytoplasmic protein input. An
antibody against TATA box binding protein (TBP) (Sigm-
Aldrich, St. Louis, U.S.A.) was used as a control for nuclear
protein input. The Western blotting analysis was repeated at least
three times.
Cell viability assays
The SW1116 cells were seeded onto 96-well plates at 2000
cells/well, cultured for 24 h, and transfected with TRAPPC4 and
control siRNA. Cell proliferation was measured using the Cell
Counting Kit-8 (CCK-8) [35]. At each time point, the SW1116
cells were incubated with 10 ml CCK-8 (Dojindo Laboratories,
Kumamoto, Japan) per well (100 ml medium/well) for 1 h at
37uC, 5% CO2. The absorbance was measured at 450 nm. Data
were expressed as the percentage of viable cells as follows: relative
viability (%)=[A450(treated)2A450(blank)]/[A450(control)2A
450(blank)]6100%.
Apoptosis assays
Apoptosis was carried out using the Annexin V assay with
Propidium iodide (PI) counterstaining (Biosea Biotechnology Co.,
LTD, Beijing, China) allowing quantification by flow cytometry.
In brief, after treated with TRAPPC4 siRNA and Control siRNA
for 48 h, both floating and trypsinized adherent cells (1610
6) were
collected and resuspended in 500 ml of binding buffer containing
10 ml of annexin-V fluorescein isothiocyanate and 5 ml of PI, then
incubated for 15 minutes in the dark at room temperature.
Analysis was immediately performed using a flow cytometer.
Tissue microarray and immunohistochemical staining for
CRC and colorectal adenoma tissues
All specimens were from patients (34 primary colorectal
adenocarcinomas and 22 adenomas) who underwent surgery at
the Shanghai Renji Hospital from July 2006 to January 2008. The
protocol had the approval of the Ethics Committee of the
Shanghai Jiao-Tong University School of Medicine, Renji
Hospital, and the research was carried out according to the
provisions of the Helsinki Declaration of 1975. Written informed
consent was obtained from all participants involved in the study.
Meanwhile, 14 specimens of normal colonic epithelium taken from
patients without colorectal cancer were used as the controls. A
tissue microarray (diameter, 1.0 mm; depth, 4 mm) was prepared
by Outdo Biotech (Shanghai, China) using standard techniques.
The tissue microarray sections were deparaffinized in xylene and
rehydrated using a graded series of ethanol. A three-step
streptavidin-biotin horseradish peroxidase method was used, and
the expressions of ERK1/2, pERK1/2, and TRAPPC4 were
examined with the primary antibodies [ERK1/2, dilution 1:100;
pERK1/2 (Thr202/Tyr204), dilution 1:100, TRAPPC4, dilution
1:50] using the LSAB+ kit (DakoCytomation, Copenhagen,
Denmark) according to the manufacturer’s instructions. The slides
were examined independently by two investigators blinded to both
clinical and pathologic data. Protein expression was quantified
based on both staining intensity, and positive frequency according
to a previously described scoring method [36].
Statistical analysis
The data from least 3 independent experiments performed in
triplicate are presented as means 6 standard deviation (SD).
Comparisons between groups were performed using the Student’s
paired t test or chi-square test (for immunohistochemistry part
only). Differences in means with a value of p,0.05 was considered
significant.
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